Academic · Private company
n-Lorem Foundation
Track this companyFree. Adds n-Lorem Foundation to your Dealase workspace and tells you when its record changes.
Clinical trials1615 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials16
- Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALSPHASE1_PHASE2 · ENROLLING_BY_INVITATION · started Dec 1, 2026ClinicalTrials.gov NCT07703462 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)PHASE1_PHASE2 · NOT_YET_RECRUITING · started Mar 1, 2026ClinicalTrials.gov NCT07423494 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALSPHASE1_PHASE2 · ENROLLING_BY_INVITATION · started Feb 19, 2026ClinicalTrials.gov NCT07743268 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene MutationPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 6, 2025ClinicalTrials.gov NCT07221760 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D)PHASE1_PHASE2 · ENROLLING_BY_INVITATION · started Oct 27, 2025ClinicalTrials.gov NCT07226297 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal DystrophyPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 28, 2025ClinicalTrials.gov NCT07177196 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide Therapy for A Single Participant With ASXL3 Gene MutationPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 19, 2025ClinicalTrials.gov NCT07197268 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 17, 2025ClinicalTrials.gov NCT06816498 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 24, 2025ClinicalTrials.gov NCT07197294 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide for A Single Participant With UBTF Gene MutationPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 5, 2025ClinicalTrials.gov NCT07588581 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALSPHASE1_PHASE2 · COMPLETED · started Nov 25, 2024ClinicalTrials.gov NCT07095712 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene MutationPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 24, 2024ClinicalTrials.gov NCT07084311 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALSPHASE1_PHASE2 · ENROLLING_BY_INVITATION · started Oct 2, 2024ClinicalTrials.gov NCT07095686 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALSPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 24, 2024ClinicalTrials.gov NCT06977451 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALSPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 16, 2024ClinicalTrials.gov NCT06392126 · fetched Nov 12, 2026
- Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene MutationPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 21, 2024ClinicalTrials.gov NCT06706388 · fetched Nov 12, 2026